Next Article in Journal
Cellular Plasticity of Mammary Epithelial Cells Underlies Heterogeneity of Breast Cancer
Next Article in Special Issue
Premature Ovarian Insufficiency: Procreative Management and Preventive Strategies
Previous Article in Journal
Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation
Previous Article in Special Issue
Intravenous Infusion of Nucleated Peripheral Blood Cells Restores Fertility in Mice with Chemotherapy-Induced Premature Ovarian Failure
Open AccessReview

The Role of Gene Therapy in Premature Ovarian Insufficiency Management

Departments of Obstetrics and Gynecology, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612, USA
*
Authors to whom correspondence should be addressed.
Biomedicines 2018, 6(4), 102; https://doi.org/10.3390/biomedicines6040102
Received: 9 September 2018 / Revised: 23 October 2018 / Accepted: 26 October 2018 / Published: 1 November 2018
  |  
PDF [702 KB, uploaded 12 November 2018]
  |  

Abstract

Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genetic disorders, and enzymatic defects) could be identified. Although hormone-replacement therapy, the principal therapeutic approach for POI, helps alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, an effective approach to manage patients with POI is highly warranted. Several mechanisms associated with POI have been identified, including the lack of function of the follicle-stimulating hormone (FSH) receptor, alterations in apoptosis control, mutations in Sal-like 4 genes, and thymulin or basonuclin-1 deficiency. The above mentioned may be good targets for gene therapy in order to correct defects leading to POI. The goal of this review is to summarize current experiences on POI studies that employed gene therapy, and to discuss possible future directions in this field. View Full-Text
Keywords: premature ovarian insufficiency; POI; gene therapy; menopause; SAL-like 4 genes; SALL4; follicle-stimulating hormone (FSH); basonuclin-1; replication-incompetent adenoviral vector; Ad; stem cells; SC premature ovarian insufficiency; POI; gene therapy; menopause; SAL-like 4 genes; SALL4; follicle-stimulating hormone (FSH); basonuclin-1; replication-incompetent adenoviral vector; Ad; stem cells; SC
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Atabiekov, I.; Hobeika, E.; Sheikh, U.; El Andaloussi, A.; Al-Hendy, A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines 2018, 6, 102.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top